Cargando…
Administration of amifostine in the stage of remission induction can benefit the patients with hematological malignancy in autologous stem cell transplantation: a retrospective study
BACKGROUND: To investigate whether the administration of amifostine in the stage of remission induction can benefit patients with hematological malignancy in autologous stem cell transplantation (ASCT). METHODS: Two historical groups of patients who received prophylactic amifostine in the stage of r...
Autores principales: | Wu, Min, Wu, Kefei, Chen, Pingping, Li, Pei, Xie, Yanhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798436/ https://www.ncbi.nlm.nih.gov/pubmed/35117881 http://dx.doi.org/10.21037/tcr-20-1366 |
Ejemplares similares
-
Peripheral hematopoietic progenitor cell mobilization for autologous transplantation in hematologic malignancies
por: Marques Jr, José Francisco Comenalli
Publicado: (2011) -
Salvaged single-unit cord blood transplantation for 26 patients with
hematologic malignancies not in remission
por: Yao, W., et al.
Publicado: (2015) -
Conditional Survival and Cause-specific Mortality after Autologous Hematopoietic Cell Transplantation for Hematological Malignancies
por: VanderWalde, Ari M., et al.
Publicado: (2012) -
Sexual Function in Women Survivors of Hematologic Malignancy after Autologous Hematopoietic Stem Cell Transplantation
por: Tsatsou, Ioanna, et al.
Publicado: (2023) -
Therapeutic Benefits of Selenium in Hematological Malignancies
por: Ehudin, Melanie A., et al.
Publicado: (2022)